Re: OTC Expert & Grey Market Restrictions
in response to
by
posted on
Nov 24, 2022 01:19PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
"Still liquid alright but how is that of any use to long time shareholders when you'd be lucky to get 10-15 cents on your 100k share holding?"
fuzzy, when we hit a home run with one of the ongoing 13 combination trials with BP, ZHCLF will move from 10-15 cents.
And as we're told Zenith Epigenetics is in discussion for a partnership or sale. I'm not putting much hope in the sale part. A sale of Zenith Epigenetics could end up selling Phase III asset Royalties and the funds ending up in the hands of ZCC. So the fact that ZHCLF can be traded on the OTC gives us the opportunity to sell our shares beforehand. That would be my preference.
Koo